Overview
- 7 FDA inspections are on record.
- 4 inspections produced a Form 483.
- The most recent recorded inspection date is 2025-07-25.
At a glance
Inspections
7
Form 483s
4
EIRs
2
Last outcome
Form 483
Inspection history
FDA inspections on record, most recent first.
| Inspection | Category | Outcome | Form 483 |
|---|---|---|---|
| 22 Jul 2025 – 25 Jul 2025 | Human Drugs | 483 | View 483 → |
| 9 Dec 2019 – 18 Dec 2019 | Human Drugs | 483 | View 483 → |
| 30 Aug 2018 – 5 Sep 2018 | Human Drugs | Clean | |
| 6 Jun 2016 – 15 Jun 2016 | Human Drugs | 483 | On file |
| 16 Sep 2013 – 27 Sep 2013 | Human Drugs | 483 | View 483 → |
| 27 Oct 2010 | Not recorded | Clean | |
| 9 Feb 2001 | Not recorded | Clean |
Observations on record
Form 483 observations cited at this site, most recent first.
25 Jul 2025
21 CFR 211.192
Investigations of discrepancies, failures
Cited by Daniel L Zheng, Ifechimere I Okafor
25 Jul 2025
21 CFR 211.22(d)
Procedures not in writing, fully followed
Cited by Daniel L Zheng, Ifechimere I Okafor
25 Jul 2025
21 CFR 211.56(a)
Sanitation--buildings not clean, free of infestation
Cited by Daniel L Zheng, Ifechimere I Okafor
25 Jul 2025
21 CFR 211.58
Buildings not maintained in good state of repair
Cited by Daniel L Zheng, Ifechimere I Okafor
25 Jul 2025
21 CFR 211.68(b)
Computer control of master formula records
Cited by Daniel L Zheng, Ifechimere I Okafor
Investigators
FDA investigators tied to this site in the record.
Daniel L Zheng1 insp.
Ifechimere I Okafor1 insp.
John P Mistler1 insp.
Jonah S Ufferfilge1 insp.
Sean R Marcsisin1 insp.
Stacey S Degarmo1 insp.
Maya M Davis1 insp.
Mark R Mcclain1 insp.
Recurring citations
CFR citation patterns observed across this site's inspections.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.22(d) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.100(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.113(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.160(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.165(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.42(c)(10) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.42(c)(10)(iv) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.56(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.58 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.67(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.68(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.84(d)(2) | Cited across public-safe Form 483 observations | 1x |
Full site report
Get the verbatim findings behind Avista Pharma Solutions, Inc.'s 4 Form 483s
Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.
- The site's full inspection history, with every Form 483 and its outcome
- Warning letters and recalls tied to the company behind it
- Whether recurring CFR citations get closed out or repeat